Please provide your email address to receive an email when new articles are posted on . The SOUL trial compared oral semaglutide vs. placebo on top of standard care in patients with type 2 diabetes ...
Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral semaglutide to ...
On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial. Last year, Novo Nordisk’s subcutaneous once-weekly (injectable) semaglutide ...
On Monday, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) approved an update to Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (oral semaglutide) label to reflect ...
Oral semaglutide reduces the risk for a composite heart failure outcome, including hospitalization and cardiovascular death, in patients with preexisting heart failure. Oral semaglutide reduces risk ...
Treatment with oral semaglutide statistically significantly reduced the risk of MACE by 14% compared with placebo. Topline results were announced from a cardiovascular outcomes study evaluating oral ...
Risk for a composite heart failure outcome was reduced by 22% with oral semaglutide in heart failure patients with type 2 diabetes and certain comorbidities, a secondary analysis of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results